BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+19.29%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$2.67B
AUM Growth
+$2.67B
(+4.9%)
Cap. Flow
+$75.1M
Cap. Flow
% of AUM
2.82%
Top 10 Holdings %
Top 10 Hldgs %
52.29%
Holding
77
New
9
Increased
18
Reduced
19
Closed
10
Top Buys
| 1 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$200M |
| 2 |
argenx
ARGX
|
$68.1M |
| 3 |
IMA
ImageneBio, Inc. Common Stock
IMA
|
$45.2M |
| 4 |
Cullinan Oncology
CGEM
|
$43.7M |
| 5 |
Merus
MRUS
|
$30.9M |
Top Sells
| 1 |
Cytokinetics
CYTK
|
$101M |
| 2 |
AMRN
Amarin Corp
AMRN
|
$56.2M |
| 3 |
Xencor
XNCR
|
$55.2M |
| 4 |
ALX Oncology
ALXO
|
$46.6M |
| 5 |
INFI
Infinity Pharmaceuticals, Inc.
INFI
|
$29.2M |
Sector Composition
| 1 | Healthcare | 98.46% |
| 2 | Financials | 0.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
FPRX
1
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $239M | 8.95% | 6,338,678 +5,300,000 | +510% | +$200M |
|
2
Olema Pharmaceuticals
OLMA
$375M
| $221M | 8.29% | 6,661,503 | – | – |
|
|
3
Merus
MRUS
$4.98B
| $152M | 5.71% | 7,285,071 +1,479,500 | +25% | +$30.9M |
|
4
Xoma
XOMA
$392M
| $144M | 5.4% | 3,530,543 -651,700 | -16% | -$26.6M |
|
5
Revolution Medicines
RVMD
$7.1B
| $135M | 5.06% | 2,943,049 +175,000 | +6% | +$8.03M |
|
6
Repare Therapeutics
RPTX
$71.7M
| $114M | 4.28% | 3,722,398 +750,207 | +25% | +$23M |
|
7
Protagonist Therapeutics
PTGX
$3.67B
| $103M | 3.84% | 3,959,451 -314,137 | -7% | -$8.14M |
|
8
Kymera Therapeutics
KYMR
$2.95B
| $102M | 3.83% | 2,630,658 | – | – |
|
9
Relay Therapeutics
RLAY
$619M
| $99.3M | 3.72% | 2,873,147 -200,000 | -7% | -$6.91M |
|
|
10
argenx
ARGX
$43.6B
| $85.3M | 3.2% | 309,599 +247,108 | +395% | +$68.1M |
|
11
ESSA Pharma
EPIX
$11.4M
| $84.5M | 3.17% | 2,908,326 -796,963 | -22% | -$23.2M |
|
12
Xenon Pharmaceuticals
XENE
$2.98B
| $62.3M | 2.34% | 3,481,778 -17,568 | -0.5% | -$314K |
|
13
Ionis Pharmaceuticals
IONS
$6.79B
| $61.3M | 2.3% | 1,364,461 | – | – |
|
14
IDEAYA Biosciences
IDYA
$2.15B
| $61.3M | 2.3% | 2,607,969 -618,800 | -19% | -$14.5M |
|
15
AC Immune
ACIU
$205M
| $57.1M | 2.14% | 7,504,579 -2,312,079 | -24% | -$17.6M |
|
16
Arcus Biosciences
RCUS
$1.13B
| $52.7M | 1.98% | 1,876,122 -876,100 | -32% | -$24.6M |
|
17
Lexicon Pharmaceuticals
LXRX
$400M
| $49.3M | 1.85% | 8,394,000 -2,569,000 | -23% | -$15.1M |
|
18
Kura Oncology
KURA
$686M
| $46.2M | 1.73% | 1,635,112 +389,200 | +31% | +$11M |
|
|
IMA
19
ImageneBio, Inc. Common Stock
IMA
$150M
| $45.2M | 1.69% | +1,599,658 | New | +$45.2M |
|
20
4D Molecular Therapeutics
FDMT
$288M
| $44.7M | 1.68% | 1,031,070 -75,000 | -7% | -$3.25M |
|
|
21
Cullinan Oncology
CGEM
$445M
| $43.7M | 1.64% | +1,049,356 | New | +$43.7M |
|
22
CytomX Therapeutics
CTMX
$336M
| $43.1M | 1.62% | 5,576,471 | – | – |
|
|
MTEM
23
DELISTED
Molecular Templates, Inc.
MTEM
| $36.1M | 1.36% | 2,864,299 +715,242 | +33% | +$9.03M |
|
24
Spero Therapeutics
SPRO
$116M
| $31.5M | 1.18% | 2,137,978 -105,300 | -5% | -$1.55M |
|
|
CBIO
25
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $28.7M | 1.08% | 9,544,262 | – | – |
|